Evidence map›Paper›PMID 36587730›Full record

ArticleJournal of proteomics2023

Proteomics-based trapping with single or multiple inactive mutants reproducibly profiles histone deacetylase 1 substrates.

Kavinda E Herath, Ishadi K M Kodikara, Mary Kay H Pflum

Open access · greenAbstract read
In one paragraph

Article in Journal of proteomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kavinda E HerathDepartment of Chemistry, Wayne State University, 5101 Cass Ave, Detroit, MI 48202, United States of America.
Ishadi K M KodikaraDepartment of Chemistry, Wayne State University, 5101 Cass Ave, Detroit, MI 48202, United States of America.
Mary Kay H PflumDepartment of Chemistry, Wayne State University, 5101 Cass Ave, Detroit, MI 48202, United States of America. Electronic address: pflum@wayne.edu.
Wayne State University · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
Pilot Project ProgramP30ES020957 · NIEHS · WAYNE STATE UNIVERSITY · PI RUNGE-MORRIS, MELISSA A · 2014 to 2021
$10.1M
Chemical Approaches to Study Protein Post-Translational ModificationsR35GM131821 · NIGMS · WAYNE STATE UNIVERSITY · PI Mary Kay H Pflum · 2019 to 2026
$4.3M
Identification of Histone Deacetylase Substrates using Trapping MutantsR01GM121061 · NIGMS · WAYNE STATE UNIVERSITY · PI PFLUM, MARY KAY H · 2016 to 2018
$829k
Orbitrap Velos with ETD for Wayne State ProteomicsS10OD010700 · OD · WAYNE STATE UNIVERSITY · PI STEMMER, PAUL M · 2012 to 2012
$575k
NCI NIH HHS P30 CA022453NIEHS NIH HHS P30 ES020957NIGMS NIH HHS R01 GM121061NIGMS NIH HHS R35 GM131821NIH HHS S10 OD010700
6 · The paper itself

Abstract

Histone deacetylase 1 (HDAC1) plays a key role in diverse cellular processes. With the aberrant expression of HDAC1 linked to many diseases, including cancers, HDAC inhibitors have been used successfully as therapeutics. HDAC1 has been predominantly associated with histone deacetylation and gene expression. Recently, non-histone substrates have revealed diverse roles of HDAC1 beyond epigenetics. To augment discovery of non-histone substrates, we introduced "substrate trapping" to enrich HDAC1 substrates using an inactive mutant. Herein, we performed a series of proteomics studies to test the robustness of HDAC1 substrate trapping. Based on our recent results documenting that different HDAC1 mutants preferentially bound different substrates, which suggested that multiple mutants could be used for efficient trapping, trapping with three single point mutants simultaneously identified several potential substrates uniquely compared to a single mutant alone. However, a greater number of biologically interesting hits were observed using only a single mutant, which suggests that the C151A HDAC1 mutant is the optimal trap. Importantly, comparing independent trials with a single mutant performed by different experimentalists and HEK293 cell populations, trapping was robust and reproducible. Based on the reproducible trapping data, carnosine N-methyltransferase 1 (CARNMT1) was validated as an HDAC1 substrate. The data document that mutant trapping is an effective method for discovery of unanticipated HDAC substrates. SIGNIFICANCE: Histone deacetylase (HDAC) proteins are well established epigenetic transcriptional regulators that deacetylate histone substrates to control gene expression. More recently, deacetylation of non-histone substrates has linked HDAC activity to functions outside of epigenetics. Given the use of HDAC inhibitor drugs as anti-cancer therapeutics, understanding the full functions of HDAC proteins in cell biology is essential to future drug design. To discover unanticipated non-histone substrates and further characterize HDAC functions, inactive mutants have been used to "trap" putative substrates, which were identified with mass spectrometry-based proteomics analysis. Here multiple trapping studies were performed to test the robustness of using inactive mutants and proteomics for HDAC substrate discovery. The data confirm the value of trapping mutants as effective tools to discover HDAC substrates and link HDAC activity to unexpected biological functions.

Indexed as

Histone Deacetylase 1ProteomicsHEK293 CellsHistone Deacetylase InhibitorsHistone DeacetylasesHumansSubstrate SpecificityHistone Deacetylase 1Histone Deacetylase InhibitorsHistone DeacetylasesHDAC inhibitorHistone deacetylaseSubstrate proteinsTrapping

Identifiers

PMID36587730
PMCPMC12750454
OpenAlexW4313333957

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.